Tert-Butyl (3R)-3-(Aminomethyl)Pyrrolidine-1-Carboxylate Hydrochloride

Amide bond construction at the primary amine under strictly anhydrous, Boc-stable conditions

Direct amidation employing tert-butyl (3R)-3-(aminomethyl)pyrrolidine-1-carboxylate hydrochloride as the amine component requires an initial neutralisation step. The hydrochloride salt is suspended in 0.4–0.6 M anhydrous N,N-dimethylformamide and treated with 2.5–3.0 equivalents of N,N-diisopropylethylamine at 0–5 °C under a dry nitrogen sweep. This liberates the free base in situ and sequesters chloride as the hydrochloride salt of the tertiary amine. Simultaneously, a separate vessel holds the carboxylic acid coupling partner (1.03–1.10 eq) pre-activated with 1.10 eq of 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) and 2.0 eq of additional DIPEA in DMF, stirred for 3–5 min at −5 °C. The pre-activation solution is then cannulated into the free amine suspension, maintaining an internal temperature below 2 °C during the addition. The resulting mixture is allowed to warm to 20–23 °C and agitated for 12–18 h. HPLC monitoring (C18, 150 × 4.6 mm, 5 µm; acetonitrile/0.1 % phosphoric acid gradient; 210 nm) confirms ≥ 97.5 % conversion by peak area. Careful temperature control prevents premature Boc deprotection—elevated exposure above 30 °C for more than 2 h in the presence of residual acidic species results in 2–5 % pyrrolidine ring deprotection, evidenced by a secondary peak at retention time 3.8 min. The crude amide is isolated by dilution with ethyl acetate, successive washes with aqueous 5 % NaHCO₃ and brine, and dried over anhydrous Na₂SO₄. This intermediate then enters a multi-kilogram synthesis route toward a clinical-stage spleen tyrosine kinase (Syk) inhibitor containing the (3R)-pyrrolidine-amide core.

What process limits arise when the hydrochloride salt is used directly in reductive amination with ketones?

A practical challenge emerges when the hydrochloride salt is charged directly into reductive amination media: the counterion neutralisation step must be precisely dosed to avoid reagent decomposition and salt interference. In a typical protocol, 1.0 eq of tert-butyl (3R)-3-(aminomethyl)pyrrolidine-1-carboxylate hydrochloride is combined with 1.20–1.35 eq of a ketone substrate in anhydrous 1,2-dichloroethane or tetrahydrofuran. To scavenge the proton from the ammonium group, 2.55–2.70 eq of DIPEA or N-methylmorpholine is introduced, forming a suspension of amine hydrochloride–base complex. After 15 min of equilibration at 20 °C, 1.40–1.60 eq of sodium triacetoxyborohydride (STAB) is added portionwise over 10 min. The batch is held at 22–25 °C with gentle agitation for 6–16 h. IPC via TLC (silica gel 60 F254; hexanes:ethyl acetate 1:2 v/v) is run at 4 h intervals. A critical quality control node is the removal of inorganic salts and unreacted STAB residues: the quench is performed with 10 % aqueous Rochelle salt under rapid stirring at 0–5 °C, otherwise emulsions irreversibly form during phase separation. The organic layer is washed, dried, and concentrated to a crude oil that is purified on a silica plug (gradient methanol in dichloromethane 0–8 % v/v). This sequence reliably yields the N-alkylated pyrrolidine with retention of the Boc group confirmed by ¹H NMR (Boc singlet at 1.44–1.47 ppm in CDCl₃). The product serves as a key cGMP-compliant intermediate per ICH Q7 §19.2 for a histamine H₃ receptor inverse agonist program, where the rigid pyrrolidine geometry is essential for target engagement.

Urea library synthesis via in-situ neutralisation and isocyanate trapping

Neutralisation of the hydrochloride with a tertiary amine base generates the free amine in situ, which is then immediately exposed to the isocyanate reagent at –10 °C in anhydrous dichloromethane. A standardized solution of the pyrrolidine salt (1.0 eq) in dichloromethane is dried over activated 4 Å molecular sieves for 30 min. The filtered solution is cooled to –15 to –10 °C in a jacketed low-temperature reactor equipped with a turbidity probe. Under argon, 2.05 eq of DIPEA is added, immediately followed by the dropwise addition of a 0.25 M solution of the isocyanate (0.98–1.02 eq) in dichloromethane over 25–30 min, maintaining the internal temperature below –8 °C. Any deviation above –5 °C during addition triggers a secondary exothermic profile that accelerates symmetric urea formation via trace water hydrolysis. The reaction mixture is stirred for 1 h at –10 °C and then quenched by addition of 0.5 mL of methanol per gram of starting material. Solvent evaporation at 30 °C/150 mbar on a rotary evaporator yields the crude trisubstituted urea. Product is precipitated by addition of n-heptane and filtered, washed, and dried under vacuum at 40 °C for 8 h. Residual triethylamine-like amine bases are controlled by headspace GC (DB-624, 30 m × 0.32 mm, 1.8 µm film; 40 °C hold 5 min, ramp to 250 °C at 15 °C/min), with acceptance below 5000 ppm per ICH Q3C Guideline for Class 3 solvents. The product is audited for enantiomeric purity by chiral HPLC: Chiralpak IA, 250 × 4.6 mm, 5 µm; mobile phase n-hexane/ethanol/diethylamine 80:20:0.1 v/v/v at 1.0 mL/min, 25 °C, detection at 220 nm; limit for the S-enantiomer ≤ 0.8 %. These ureas constitute a fragment library used in the development of dipeptidyl peptidase-4 (DPP-4) inhibitors with prolonged off-rate kinetics.

Sulfonamide derivatisation for sulfonamide-based pharmacophores: reaction sequence and impurity control

At –5 to 0 °C in anhydrous tetrahydrofuran, the free amine generated from the hydrochloride — after treatment with 2.5 eq of DIPEA — reacts with sulfonyl chlorides to afford structurally diverse sulfonamides. The substrate hydrochloride is charged first, followed by THF (Kf ≤ 100 ppm water) to achieve a 0.3 M concentration. DIPEA is added dropwise, and the mixture is stirred for 10 min before a solution of the sulfonyl chloride (1.15 eq) in THF is introduced at a rate that keeps the internal temperature below 2 °C. A slight excess of the electrophile is mandatory because the liberated HCl from the hydrochloride salt partially consumes the sulfonyl chloride via hydrolysis if moisture ingress exceeds 50 ppm. The batch is agitated at 0–5 °C for 1.5 h and then allowed to warm to 20 °C for 30 min. Quenching is performed with 10 % aqueous citric acid monohydrate, which decomposes unreacted sulfonyl chloride efficiently without attacking the Boc group (pH 3.5–4.0 measured after phase separation). The organic layer is washed, dried, and concentrated. The crude product is analysed by reverse-phase HPLC: an Inertsil ODS-3 column (150 × 4.6 mm, 5 µm), mobile phase acetonitrile/0.05 % trifluoroacetic acid water gradient 30–90 % over 20 min, flow 1.2 mL/min, UV at 254 nm. Any bis-sulfonylation side product arising from the pyrrolidine ring nitrogen is quantified as a critical impurity, with a control limit ≤ 2.0 area%. The main sulfonamide fraction is isolated by silica gel flash chromatography (ethyl acetate/hexane gradient) and crystallised from diethyl ether to provide a single polymorph with melting onset 117–119 °C. The final sulfonamide constitutes a key intermediate for a carbonic anhydrase IX inhibitor candidate studied in hypoxic tumour microenvironments, where the (3R) configuration dictates isoform selectivity.

When constructing constrained bicyclic scaffolds, the free amine undergoes intramolecular reductive amination after Boc removal

Removal of the Boc group under acidic conditions followed by neutralisation liberates the (3R)-3-(aminomethyl)pyrrolidine free base, which is then subjected to intramolecular cyclisation to form an annulated bicyclic system. The protected hydrochloride (1.0 g scale) is dissolved in dichloromethane (10 mL) and treated with trifluoroacetic acid (10 mL) at 0 °C. The solution is stirred for 30 min at 0–5 °C, after which volatiles are removed under reduced pressure at 25 °C, co-evaporating twice with toluene (15 mL) to azeotrope residual TFA. The resulting TFA salt is dissolved in methanol (15 mL) and neutralised with Amberlyst A-21 free-base resin (3.5 g, pre-washed with methanol) over 45 min with gentle agitation. Filtration and concentration deliver the free diamine as a viscous oil. This intermediate is immediately dissolved in anhydrous methanol (20 mL) containing the internal ketone or aldehyde functional handle already present in the substrate backbone (0.95 eq relative to diamine). The pH is adjusted to 5.5–6.0 with acetic acid, and sodium cyanoborohydride (1.5 eq) is added in one portion at 0 °C. The mixture is stirred at 25 °C for 7–10 h. Routine monitoring with LC-MS confirms mass of the targeted 3,7-diazabicyclo[3.3.0]octane or analogous fused heterocycle. Purification employs strong cation exchange (SCX) resin elution with 2 M ammonia in methanol. The resulting bicyclic scaffold is obtained with enantiomeric excess ≥ 99.2 % as determined by chiral CE using a boric acid–sodium tetraborate buffer at pH 9.2 and 50 mM heptakis-(2,6-di-O-methyl)-ꞵ-cyclodextrin as selector. The material is further elaborated into a direct thrombin inhibitor targeting dabigatran-resistant mutant enzymes, relying on the pre-organized bicyclic framework for potency.

Integrating a non-natural amino acid surrogate into Fmoc solid-phase peptide elongation

When employing Fmoc-based solid-phase peptide synthesis on aminomethyl polystyrene resin, the chiral amine is coupled as a branching unit via its primary amine group, necessitating careful stoichiometric balancing to prevent double incorporation. Wang resin pre-loaded with the first Fmoc-amino acid (0.1 mmol, loading 0.65 mmol/g) is swollen in N-methyl-2-pyrrolidone for 30 min. Fmoc deprotection proceeds with 20 % piperidine in DMF (2 × 5 min), followed by DMF washing and Kaiser test confirmation. The pyrrolidine hydrochloride (3.0 eq relative to resin loading) is neutralised with 6.5 eq of DIPEA in DMF just before addition to the resin. The coupling cocktail contains 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU, 2.95 eq) and DIPEA (6.0 eq) in a total volume delivering a 0.25 M concentration of the amino acid surrogate. The resin slurry is agitated for 2 h at 25 °C under nitrogen. Nin-positive beads after a second coupling (1.5 eq) trigger a capping step with acetic anhydride/pyridine/DMF 5:6:89 v/v/v for 20 min. Following coupling, the Boc protecting group is selectively removed on-resin using TFA/triethylsilane/H₂O 95:2.5:2.5 v/v/v for 45 min, while the peptide backbone’s Fmoc and side-chain protecting groups remain intact—this selectivity is verified by Fmoc release assay at 301 nm showing ≤ 4 % premature deprotection. The freed pyrrolidine secondary amine is then available for further chain elongation. Peptide cleavage from the resin uses Reagent K (TFA/phenol/water/thioanisole/ethanedithiol 82.5:5:5:5:2.5 v/v) for 3 h at room temperature. The crude linear peptide is purified by preparative HPLC and lyophilised, with identity confirmed by HRMS. The resulting (3R)-pyrrolidine-embedded peptidomimetic serves as a conformationally constrained β-turn mimic in a cyclic heptapeptide targeting the Keap1-Nrf2 protein–protein interaction interface, where the rigid aminomethylpyrrolidine arm positions a critical glutamate residue for Arg415 binding.